Pure Global AI
NCT06242132Recruiting

Clopidogrel Versus Cilostazol in Ischemic Stroke

Clopidogrel Versus Cilostazol in Ischemic Stroke, a Randomized Controlled Trial
Kafrelsheikh UniversityPhase 3ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Ischemic Stroke
Drug/Device/Intervention
Clopidogrel tablet
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Kafrelsheikh University
Location
Kafr Ash Shaykh, Egypt
Timeline & enrollment
Phase
Phase 3
Start date
Feb 01, 2024
End date
Jan 30, 2025
Enrollment
900 participants
Primary outcome

rate of new ischemic stroke,Rate of drug-related hemorrhagic complications

Summary

Along with the current clinical trial, the efficacy and safety of a 300 mg loading dose of
 ticagrelor administered within 24 hours of the first-ever moderate to severe ischemic stroke
 compared to 200 mg cilostazol were assessed through NIHSS, mRS, and possible adverse effects.

ICD-10 classifications
Stroke, not specified as haemorrhage or infarctionSequelae of stroke, not specified as haemorrhage or infarctionCerebral infarctionCerebral infarction, unspecifiedOther cerebral infarction
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06242132
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06242132 through Pure Global AI's free database. This Phase 3 trial is sponsored by Kafrelsheikh University and is currently Recruiting. The study focuses on Ischemic Stroke. Target enrollment is 900 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.